V930
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cancers Expressing HER-2 and/or CEA
Conditions
Cancers Expressing HER-2 and/or CEA
Trial Timeline
Sep 1, 2005 → Sep 1, 2008
NCT ID
NCT00250419About V930
V930 is a phase 1 stage product being developed by Merck for Cancers Expressing HER-2 and/or CEA. The current trial status is completed. This product is registered under clinical trial identifier NCT00250419. Target conditions include Cancers Expressing HER-2 and/or CEA.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00250419 | Phase 1 | Completed |
| NCT00721461 | Phase 1 | Completed |
Competing Products
20 competing products in Cancers Expressing HER-2 and/or CEA